ClearNote Health (formerly Bluestar Genomics) – Cancer detection company enabling people at risk for high-mortality cancers to live longer, healthier lives.

They focus on developing non-invasive tests to detect cancer through a standard blood draw earlier than existing methods by harnessing the power of epigenomics. They apply their proprietary epigenomic platform, combining biology and artificial intelligence, to identify DNA-based changes in biology as cancer develops.

With lead programs in non-invasive early detection of pancreatic and ovarian cancers in patients at the highest risk for these diseases. Headquartered in the U.S, the company’s CLIA and CAP-accredited laboratory is located in San Diego, Calif., with additional presence in the San Francisco Bay Area and internationally.


Biotechnology

Clearnote Health

Dave Mullarkey

Danielle Scelfo

Gulfem D. Guler

Anna Bergamaschi

Eric Nilson

Samuel Levy

Wayne Volkmuth

Jim Vaughn

The executive team at Bluestar Genomics has a wealth of experience in the biotech industry. The team members have worked as adjunct professors, staff physicians, and executives at various companies including Quanticel Pharmaceuticals, Celgene, and Impact Genomics. They also have distinguished research careers, with fellowships from universities such as Yale, George Washington, and Leeds.

CEO and Executive Team

Board of Directors

Leadership Team

CEO and Executive Team

About

Team members

Other teams at Clearnote Health

Board of Directors

Leadership Team